| Literature DB >> 24720916 |
Javed Butler1, Gregg C Fonarow2, Michael R Zile3, Carolyn S Lam4, Lothar Roessig5, Erik B Schelbert6, Sanjiv J Shah7, Ali Ahmed8, Robert O Bonow7, John G F Cleland9, Robert J Cody10, Ovidiu Chioncel11, Sean P Collins12, Preston Dunnmon13, Gerasimos Filippatos14, Martin P Lefkowitz15, Catherine N Marti16, John J McMurray17, Frank Misselwitz5, Savina Nodari18, Christopher O'Connor19, Marc A Pfeffer20, Burkert Pieske21, Bertram Pitt22, Giuseppe Rosano23, Hani N Sabbah24, Michele Senni25, Scott D Solomon20, Norman Stockbridge13, John R Teerlink26, Vasiliki V Georgiopoulou16, Mihai Gheorghiade7.
Abstract
The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is projected to worsen. To date, there are no approved therapies available for reducing mortality or hospitalizations for these patients. The pathophysiology of HFpEF is complex and includes alterations in cardiac structure and function, systemic and pulmonary vascular abnormalities, end-organ involvement, and comorbidities. There remain major gaps in our understanding of HFpEF pathophysiology. To facilitate a discussion of how to proceed effectively in future with development of therapies for HFpEF, a meeting was facilitated by the Food and Drug Administration and included representatives from academia, industry, and regulatory agencies. This document summarizes the proceedings from this meeting.Entities:
Keywords: epidemiology; heart failure; preserved ejection fraction; prognosis; treatment
Mesh：
Year: 2014 PMID： 24720916 PMCID： PMC4028447 DOI： 10.1016/j.jchf.2013.10.006
Source DB: PubMed Journal: JACC Heart Fail ISSN： 2213-1779 Impact factor: 12.035